What is the appropriate management for a patient with ferritin 10.6 ng/mL, total iron‑binding capacity 460 µg/dL, transferrin saturation 13 %, erythrocyte sedimentation rate 22 mm/hr, and mean corpuscular volume 82 fL?

Iron Deficiency Anemia Requiring Treatment and Gastrointestinal Evaluation

This patient has confirmed iron deficiency anemia (ferritin 10.6 ng/mL, transferrin saturation 13%, TIBC 460 µg/dL) and requires immediate oral iron supplementation along with bidirectional endoscopy to identify the source of blood loss.

Diagnostic Confirmation

Your patient's laboratory values definitively establish iron deficiency anemia:

• Ferritin 10.6 ng/mL is well below the diagnostic threshold of <45 ng/mL 1, and even below the highly specific cutoff of <15 ng/mL
• Transferrin saturation 13% confirms iron deficiency (normal >20%)
• TIBC 460 µg/dL is elevated, consistent with iron deficiency (the body increases iron-binding capacity when iron stores are depleted)
• MCV 82 fL is at the lower end of normal, which can occur in early or mild iron deficiency before frank microcytosis develops
• ESR 22 mm/hr is mildly elevated but not high enough to suggest significant inflammation that would confound ferritin interpretation

The slightly elevated ESR does not change the interpretation here—ferritin <100 ng/mL with low transferrin saturation confirms true iron deficiency even in the presence of mild inflammation 2.

Immediate Management: Iron Replacement

Start oral iron supplementation immediately 2, 3:

• Ferrous sulfate 325 mg (65 mg elemental iron) every other day on an empty stomach is the preferred regimen—every-other-day dosing improves absorption compared to daily dosing 3
• If not tolerated on empty stomach, take with meals (preferably with meat protein and 500 mg vitamin C to enhance absorption) 2
• Alternative formulations include ferrous fumarate, ferrous gluconate, or ferrous bisglycinate if side effects occur 2
• Reassess response in 2-4 weeks with repeat hemoglobin and reticulocyte count 3

Intravenous iron should be reserved for: oral intolerance, inadequate response after 2-4 weeks, malabsorption conditions, or ongoing significant blood loss 2, 3.

Mandatory Gastrointestinal Evaluation

The patient requires bidirectional endoscopy (EGD and colonoscopy) performed at the same session 1. This is a strong recommendation based on moderate-quality evidence for asymptomatic postmenopausal women and men with iron deficiency anemia.

Before Endoscopy, Rule Out Common Causes:

1. Helicobacter pylori testing (stool antigen or urea breath test)—common cause of iron malabsorption 2
2. Celiac disease serologies (tissue transglutaminase IgA with total IgA)—affects iron absorption 2
3. Detailed menstrual history if premenopausal woman
4. Dietary assessment for inadequate intake, vegetarian/vegan diet
5. Medication review for NSAIDs, anticoagulants, antiplatelet agents
6. Blood donation history

Proceed with Bidirectional Endoscopy Unless:

• Clear alternative explanation identified (heavy menstrual bleeding in premenopausal woman with documented improvement after treatment)
• Patient is young with obvious dietary deficiency
• Recurrent blood loss is 94% responsible for iron deficiency anemia in adults 3

Treatment Targets

Goal ferritin: >100 ng/mL 4
Goal hemoglobin: 10-12 g/dL or normalization 4
Goal transferrin saturation: >20% 4

Continue iron supplementation for 3-6 months after normalization of hemoglobin to replete iron stores.

Critical Pitfalls to Avoid

• Do not delay endoscopy while treating with iron—gastrointestinal malignancy must be excluded
• Do not assume dietary deficiency alone in men or postmenopausal women without thorough evaluation
• Do not use the MCV alone to exclude iron deficiency—this patient's MCV is 82 fL (normal range), yet has severe iron deficiency. MCV becomes microcytic late in iron deficiency 5
• Do not order bone marrow biopsy—ferritin <10.6 ng/mL is diagnostic and more specific than bone marrow iron staining 6

If Oral Iron Fails

After 2-4 weeks of adequate oral iron therapy, expect:

• Reticulocytosis (increased reticulocyte count)
• Hemoglobin increase of 1-2 g/dL

If no response occurs, consider:

• Non-adherence (50% of patients have decreased adherence due to GI side effects) 3
• Ongoing blood loss exceeding replacement
• Malabsorption (celiac disease, H. pylori, inflammatory bowel disease, atrophic gastritis)
• Switch to intravenous iron 2, 3

Modern IV iron formulations (ferric carboxymaltose, iron sucrose, ferumoxytol) have hypersensitivity rates <1% 3.